Fundz

Imprimed Raises $23 Million Series A Round To Expand Its Revolutionary Ai-Powered Cancer Treatment Technology

PRIVATEDec 19, 2023

Amount Raised

$23 Million

Round Type

Series A

Mountain ViewBiotechnologyHealth CareArtificial IntelligenceMedicalHealth Diagnostics

Investors

ByucksanMurex PartnersSamyang Chemical GroupIgnite Innovation FundKdb Silicon ValleySk TelecomHrz Han River PartnersSbva

Description

ImpriMed, a leading precision medicine startup focused on leveraging artificial intelligence to improve cancer treatment, today announced the close of a $23 million Series A funding round, led by SBVA. HRZ Han River Partners, SK Telecom, KDB Silicon Valley, Ignite Innovation Fund, Samyang Chemical Group, Murex Partners, and Byucksan also participated in this round. The funding will enable ImpriMed to expand its revolutionary drug response prediction technology beyond veterinary medicine into human oncology, increase headcount, and broaden its business development and research and development pipeline.

Company Information

Company

ImpriMed

Location

Mountain View, California, United States

About

ImpriMed provides cutting-edge personalized medicine easily accessible for pets with blood cancer diseases. ImpriMed’s key product, Personalized Prediction Profile, has been used by board-certified veterinary oncologists, helping over 4,000 dogs with lymphoma and leukemia. With ImpriMed’s services, veterinarians make their treatment decisions quickly and with confidence. This innovative approach to cancer care has been published in a scientific journal and presented at major conferences and is supported by over 200 veterinary oncologists at 80+ specialty hospitals in the US.

Fundz sees it the moment ImpriMed raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.

Related People

1 contact
Predictive Intelligence
Strategic

ML-powered predictions for ImpriMed's next move

See what Strategic adds

Funding Insights

What this usually means
Typical timeline to Series B
Series A companies typically raise their next round in 10-18 months

ImpriMed raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.

145 of these a day, filtered to the companies you pick, with the decision-maker attached.

5 screens from a live account. No signup.

Fundz is a real-time business intelligence platform powered by agentic AI that proactively delivers personalized daily signals, including funding rounds, executive changes, M&A activity, 13F institutional filings, SEC 8-K events, investor activity, and website modifications, based on each user's watchlist and ICP. A trusted data source at firms such as BlackRock, Oracle, Kleiner Perkins, LinkedIn, HubSpot, and Cloudflare, Fundz democratizes the institutional-grade intelligence that previously required a PitchBook or Bloomberg terminal. Features include FundzWatch™ for automated website change detection, Daily Briefing for AI-powered daily briefings, and unified cross-signal alerts across 281,000+ organizations. Developers and data teams can access these signals programmatically via the Fundz Funding Data API, with transparent published pricing.